

Market Announcement

28 October 2021

Antisense Therapeutics Limited (ASX: ANP) – Trading Halt

Description

The securities of Antisense Therapeutics Limited ('ANP') will be placed in trading halt at the request of ANP, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 1 November 2021 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

28 October 2021

Melissa Kostopoulos
Compliance Adviser
Listings Compliance (Melbourne)
ASX Compliance Limited

Email: Melissa.kostopoulos@asx.com.au
TradingHaltsMelbourne@asx.com.au

Dear Melissa,

Request for Trading Halt for Antisense Therapeutics Limited

In accordance with ASX Listing Rule 17.1, the Company requests an immediate trading halt in respect of its securities (ASX Code: ANP), pending release in respect of reporting on the European Medicines Agency Paediatric Committee Opinion adoption of the Paediatric Investigation Plan for ATL1102 for the treatment of Duchenne muscular dystrophy.

In requesting the trading halt, the Company provides the following information:

- The trading halt is requested in respect of preparation and finalising the release of the European Medicines Agency Paediatric Committee Opinion adoption of the Paediatric Investigation Plan for ATL1102 for the treatment of Duchenne muscular dystrophy;
- Unless otherwise requested by the Company, ANP requests the trading halt to remain in place until the earlier of the release of an announcement or the morning of Monday 01 November 2021; and
- The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely,



Phillip Hains
Company Secretary